CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for tough prostate cancer
Disease control OngoingThis study tests whether adding cediranib to olaparib works better than olaparib alone for men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. About 90 men will take part. The goal is to see if the combination slows cancer growth…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New hope for men with Tough-to-Treat prostate cancer?
Disease control OngoingThis study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific gene change (SPOP mutation) and has stopped responding to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 can shr…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
Promising combo targets tough prostate cancer in bones
Disease control OngoingThis study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. It tests two drugs together: olaparib, which stops cancer cells from repairing themselves, and radium-223, a radioactive drug that targets bone tu…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for men with hard-to-treat prostate cancer: adding immunotherapy to existing drug
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab can help men whose advanced prostate cancer has stopped responding to the hormone therapy enzalutamide. About 58 men with castration-resistant prostate cancer that has spread will receive pembrolizumab while con…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug cocktail shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in men with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combo can lower PSA lev…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Smart scans may boost radiation success in advanced prostate cancer
Disease control OngoingThis study tests whether a special PET scan (PSMA PET) can help pick the right patients for radium-223 (Ra-223) radiation therapy. Ra-223 targets bone tumors in men with castration-resistant prostate cancer that has spread to the bones. The goal is to see if using the scan leads …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New hope for tough prostate cancer: drug cocktail trial underway
Disease control OngoingThis study tests different combinations of approved drugs to treat men with advanced prostate cancer that has spread and no longer responds to hormone therapy. About 196 men will receive either a standard hormone-blocking combo or that combo plus an immunotherapy or chemotherapy …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug combo shows promise for tough prostate cancer
Disease control OngoingThis study tests two drugs, golimumab and apalutamide, in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if blocking inflammation and male hormones together can shrink tumors or slow the cancer. Eight men partic…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Double-Drug attack shows promise for tough prostate cancer
Disease control OngoingThis study tests whether adding a chemotherapy drug (cabazitaxel) to a hormone therapy (abiraterone) works better than hormone therapy alone for men with advanced prostate cancer that has spread and stopped responding to initial treatment. About 223 men who have already received …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Targeted drug cocktail shows promise for rare prostate cancer mutation
Disease control OngoingThis study tests a two-drug combination (niraparib/abiraterone plus prednisone) in men with a specific genetic change (SPOP mutation) in their advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the drugs can shrink t…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug cocktail shows promise in slowing tough prostate cancer
Disease control OngoingThis study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New combo therapy aims to shrink advanced cancers
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other drugs and radiation in people with advanced cancers that have not responded to standard treatments. About 173 adults with various solid tumors, including prostate cancer, will re…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New combo therapy aims to boost immune response in hard-to-treat prostate cancer
Disease control OngoingThis study looks at how well the hormone drug enzalutamide works alone or with a targeted radiation therapy (radium-223) in 30 men with advanced prostate cancer that has spread to bones and no longer responds to standard hormone treatment. The goal is to see changes in the cancer…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New drug cocktail shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a new drug (berzosertib) combined with standard chemotherapy (carboplatin) in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if this combination shrinks tumors or lowers PSA l…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Immunotherapy plus chemo shows promise against Tough-to-Treat cancers
Disease control OngoingThis early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for tough prostate cancer: Two-Drug attack after chemo
Disease control OngoingThis study tests a two-step treatment for men with an aggressive form of prostate cancer that has spread. First, patients get chemotherapy plus an immunotherapy drug. Then, they take a maintenance pill (niraparib) either alone or with more immunotherapy. The goal is to see if thi…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC